免疫检查点抑制剂相关风湿性不良反应的诊疗及预测进展
Progress in Diagnosis, Treatment and Prediction of Rheumatic Adverse Events Associated with Immune Checkpoint Inhibitors
摘要: 随着免疫检查点抑制剂(ICIs)在肿瘤治疗领域的广泛应用，其引发的免疫相关不良反应(irAEs)也备受关注。irAEs可发生于全身任何器官系统，其中以肌肉骨骼表现为主的风湿性irAEs在临床中常有报道，如炎性关节炎、风湿性多肌痛、肌炎、血管炎等，早期识别和干预此类不良反应对改善肿瘤患者预后尤为重要，而寻找有助于精确预测irAEs发生的生物标志物也成为未来研究的热点。因此，本文就ICIs相关风湿性不良反应的临床特点、诊断和鉴别诊断、管理及潜在预测性标志物加以综述，以加强临床医师对此类疾病的认识。
Abstract: With the wide application of immune checkpoint inhibitors (ICIs) in the field of tumor therapy, the immune-related adverse events (irAEs) induced by ICIs have also attracted much attention. The irAEs can occur in any organ system, among which rheumatic irAEs which are mainly characterized by musculoskeletal manifestations have often been reported in clinic, such as inflammatory arthritis, polymyalgia rheumatica, myositis, vasculitis. Early identification and intervention of these adverse events are important for improving prognosis of cancer patients. Finding biomarkers that can help to accurately predict the development of irAEs will be a focus of future research. Therefore, this article reviews the clinical features, diagnosis, differential diagnosis, management and potential predictive markers of ICIs-associated rheumatic adverse events to enhance clinicians’ understanding of these diseases.
文章引用：李悦, 刘宇宏. 免疫检查点抑制剂相关风湿性不良反应的诊疗及预测进展[J]. 临床医学进展, 2024, 14(9): 503-510. https://doi.org/10.12677/acm.2024.1492489

参考文献

[1] Kruger, S., Ilmer, M., Kobold, S., Cadilha, B.L., Endres, S., Ormanns, S., et al. (2019) Advances in Cancer Immunotherapy 2019—Latest Trends. Journal of Experimental & Clinical Cancer Research, 38, Article No. 268. [Google Scholar] [CrossRef] [PubMed]
[2] Shiravand, Y., Khodadadi, F., Kashani, S.M.A., Hosseini-Fard, S.R., Hosseini, S., Sadeghirad, H., et al. (2022) Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology, 29, 3044-3060. [Google Scholar] [CrossRef] [PubMed]
[3] Das, S. and Johnson, D.B. (2019) Immune-Related Adverse Events and Anti-Tumor Efficacy of Immune Checkpoint Inhibitors. Journal for ImmunoTherapy of Cancer, 7, 306. [Google Scholar] [CrossRef] [PubMed]
[4] Ramos-Casals, M., Brahmer, J.R., Callahan, M.K., Flores-Chávez, A., Keegan, N., Khamashta, M.A., et al. (2020) Immune-Related Adverse Events of Checkpoint Inhibitors. Nature Reviews Disease Primers, 6, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[5] Melissaropoulos, K., Klavdianou, K., Filippopoulou, A., Kalofonou, F., Kalofonos, H. and Daoussis, D. (2020) Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 21, Article 3389. [Google Scholar] [CrossRef] [PubMed]
[6] Wu, Z., Chen, Q., Qu, L., Li, M., Wang, L., Mir, M.C., et al. (2022) Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-Analysis. European Urology, 81, 414-425. [Google Scholar] [CrossRef] [PubMed]
[7] Johnson, D.B., Nebhan, C.A., Moslehi, J.J. and Balko, J.M. (2022) Immune-checkpoint Inhibitors: Long-Term Implications of Toxicity. Nature Reviews Clinical Oncology, 19, 254-267. [Google Scholar] [CrossRef] [PubMed]
[8] Carlino, M.S., Larkin, J. and Long, G.V. (2021) Immune Checkpoint Inhibitors in Melanoma. The Lancet, 398, 1002-1014. [Google Scholar] [CrossRef] [PubMed]
[9] Abdel-Wahab, N. and Suarez-Almazor, M.E. (2019) Frequency and Distribution of Various Rheumatic Disorders Associated with Checkpoint Inhibitor Therapy. Rheumatology, 58, vii40-vii48. [Google Scholar] [CrossRef] [PubMed]
[10] Cappelli, L.C. and Bingham, C.O. (2021) Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications. Arthritis & Rheumatology, 73, 553-565. [Google Scholar] [CrossRef] [PubMed]
[11] Zhong, L., Wu, Q., Chen, F., Liu, J. and Xie, X. (2021) Immune-Related Adverse Events: Promising Predictors for Efficacy of Immune Checkpoint Inhibitors. Cancer Immunology, Immunotherapy, 70, 2559-2576. [Google Scholar] [CrossRef] [PubMed]
[12] Pundole, X., Abdel-Wahab, N. and Suarez-Almazor, M.E. (2019) Arthritis Risk with Immune Checkpoint Inhibitor Therapy for Cancer. Current Opinion in Rheumatology, 31, 293-299. [Google Scholar] [CrossRef] [PubMed]
[13] Shen, P., Deng, X., Hu, Z., Chen, Z., Huang, Y., Wang, K., et al. (2021) Rheumatic Manifestations and Diseases from Immune Checkpoint Inhibitors in Cancer Immunotherapy. Frontiers in Medicine, 8, Article 762247. [Google Scholar] [CrossRef] [PubMed]
[14] Jeurling, S. and Cappelli, L.C. (2020) Treatment of Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis. Current Opinion in Rheumatology, 32, 315-320. [Google Scholar] [CrossRef] [PubMed]
[15] Leipe, J. and Mariette, X. (2019) Management of Rheumatic Complications of ICI Therapy: A Rheumatology Viewpoint. Rheumatology, 58, vii49-vii58. [Google Scholar] [CrossRef] [PubMed]
[16] Iskandar, A., Hwang, A. and Dasanu, C.A. (2018) Polymyalgia Rheumatica Due to Pembrolizumab Therapy. Journal of Oncology Pharmacy Practice, 25, 1282-1284. [Google Scholar] [CrossRef] [PubMed]
[17] Manzo, C., Isetta, M., Natale, M. and Castagna, A. (2020) Identification and Classification of Polymyalgia Rheumatica (PMR) and PMR-Like Syndromes Following Immune Checkpoint Inhibitors (ICIs) Therapy: Discussion Points and Grey Areas Emerging from a Systematic Review of Published Literature. Medicines, 7, Article 68. [Google Scholar] [CrossRef] [PubMed]
[18] Calabrese, C., Cappelli, L.C., Kostine, M., Kirchner, E., Braaten, T. and Calabrese, L. (2019) Polymyalgia Rheumatica-Like Syndrome from Checkpoint Inhibitor Therapy: Case Series and Systematic Review of the Literature. RMD Open, 5, e000906. [Google Scholar] [CrossRef] [PubMed]
[19] Martin de Fremont, G., Belkhir, R., Henry, J., Voisin, A.L., Lambotte, O., Besson, F.L., et al. (2020) Features of Polymyalgia Rheumatica-Like Syndrome after Immune Checkpoint Inhibitor Therapy. Annals of the Rheumatic Diseases, 81, e52. [Google Scholar] [CrossRef] [PubMed]
[20] van der Geest, K.S.M., Sandovici, M., Rutgers, A., Hiltermann, T.J.N., Oosting, S.F., Slart, R.H.J.A., et al. (2020) Imaging in Immune Checkpoint Inhibitor-Induced Polymyalgia Rheumatica. Annals of the Rheumatic Diseases, 81, e210. [Google Scholar] [CrossRef] [PubMed]
[21] van der Geest, K.S.M., Sandovici, M., Rutgers, A., Hiltermann, T.J.N., Oosting, S.F., Slart, R.H.J.A., et al. (2020) Management of Immune Checkpoint Inhibitor-Induced Polymyalgia Rheumatica. Annals of the Rheumatic Diseases, 81, e263. [Google Scholar] [CrossRef] [PubMed]
[22] Touat, M., Maisonobe, T., Knauss, S., Ben Hadj Salem, O., Hervier, B., Auré, K., et al. (2018) Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer. Neurology, 91, e985-e994. [Google Scholar] [CrossRef] [PubMed]
[23] Anquetil, C., Salem, J., Lebrun-Vignes, B., Johnson, D.B., Mammen, A.L., Stenzel, W., et al. (2018) Immune Checkpoint Inhibitor-Associated Myositiss: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution. Circulation, 138, 743-745. [Google Scholar] [CrossRef] [PubMed]
[24] Wang, D.Y., Salem, J., Cohen, J.V., Chandra, S., Menzer, C., Ye, F., et al. (2018) Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. JAMA Oncology, 4, 1721-1728. [Google Scholar] [CrossRef] [PubMed]
[25] Gremese, E., Alivernini, S., Ferraccioli, E.S. and Ferraccioli, G. (2020) Checkpoint Inhibitors (CPI) and Autoimmune Chronic Inflammatory Diseases (acids): Tolerance and Loss of Tolerance in the Occurrence of Immuno-Rheumatologic Manifestations. Clinical Immunology, 214, Article ID: 108395. [Google Scholar] [CrossRef] [PubMed]
[26] Cappelli, L.C. and Bingham, C.O. (2020) Spectrum and Impact of Checkpoint Inhibitor-Induced irAEs. Nature Reviews Rheumatology, 17, 69-70. [Google Scholar] [CrossRef] [PubMed]
[27] 中国抗癌协会肿瘤支持治疗专业委员会, 中国抗癌协会肿瘤临床化疗专业委员会. 免疫检查点抑制剂相关神经不良反应诊治中国专家共识(2022版) [J]. 中华肿瘤杂志, 2022, 44(9): 935-941.
[28] Pathak, R., Katel, A., Massarelli, E., Villaflor, V.M., Sun, V. and Salgia, R. (2021) Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. The Oncologist, 26, 1052-1061. [Google Scholar] [CrossRef] [PubMed]
[29] Solimando, A.G., Crudele, L., Leone, P., Argentiero, A., Guarascio, M., Silvestris, N., et al. (2020) Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside. International Journal of Molecular Sciences, 21, Article 3054. [Google Scholar] [CrossRef] [PubMed]
[30] Kostine, M., Finckh, A., Bingham, C.O., Visser, K., Leipe, J., Schulze-Koops, H., et al. (2020) EULAR Points to Consider for the Diagnosis and Management of Rheumatic Immune-Related Adverse Events Due to Cancer Immunotherapy with Checkpoint Inhibitors. Annals of the Rheumatic Diseases, 80, 36-48. [Google Scholar] [CrossRef] [PubMed]
[31] Salem, J., Allenbach, Y., Vozy, A., Brechot, N., Johnson, D.B., Moslehi, J.J., et al. (2019) Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. New England Journal of Medicine, 380, 2377-2379. [Google Scholar] [CrossRef] [PubMed]
[32] Hu, J., Florido, R., Lipson, E.J., Naidoo, J., Ardehali, R., Tocchetti, C.G., et al. (2019) Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors. Cardiovascular Research, 115, 854-868. [Google Scholar] [CrossRef] [PubMed]
[33] Gkiozos, I., Kopitopoulou, A., Kalkanis, A., Vamvakaris, I.N., Judson, M.A. and Syrigos, K.N. (2018) Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors. Journal of Thoracic Oncology, 13, 1076-1082. [Google Scholar] [CrossRef] [PubMed]
[34] Warner, B.M., Baer, A.N., Lipson, E.J., Allen, C., Hinrichs, C., Rajan, A., et al. (2019) Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. The Oncologist, 24, 1259-1269. [Google Scholar] [CrossRef] [PubMed]
[35] Ramos-Casals, M., Maria, A., Suarez-Almazor, M.E., et al. (2019) Sicca/Sjogren’s Syndrome Triggered by PD-1/PD-L1 Checkpoint Inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clinical and Experimental Rheumatology, 118, 114-122.
[36] Raschi, E., Antonazzo, I.C., Poluzzi, E. and De Ponti, F. (2019) Drug-Induced Systemic Lupus Erythematosus: Should Immune Checkpoint Inhibitors Be Added to the Evolving List? Annals of the Rheumatic Diseases, 80, e120. [Google Scholar] [CrossRef] [PubMed]
[37] Hamaguchi, Y. (2022) Drug-induced Scleroderma-Like Lesion. Allergology International, 71, 163-168. [Google Scholar] [CrossRef] [PubMed]
[38] Draghi, A., Borch, T.H., Radic, H.D., Chamberlain, C.A., Gokuldass, A., Svane, I.M., et al. (2019) Differential Effects of Corticosteroids and Anti‐TNF on Tumor‐Specific Immune Responses: Implications for the Management of Iraes. International Journal of Cancer, 145, 1408-1413. [Google Scholar] [CrossRef] [PubMed]
[39] Mitchell, E.L., Lau, P.K.H., Khoo, C., Liew, D., Leung, J., Liu, B., et al. (2018) Rheumatic Immune-Related Adverse Events Secondary to Anti-Programmed Death-1 Antibodies and Preliminary Analysis on the Impact of Corticosteroids on Anti-Tumour Response: A Case Series. European Journal of Cancer, 105, 88-102. [Google Scholar] [CrossRef] [PubMed]
[40] Arbour, K.C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., et al. (2018) Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients with Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 36, 2872-2878. [Google Scholar] [CrossRef] [PubMed]
[41] Braaten, T.J., Brahmer, J.R., Forde, P.M., Le, D., Lipson, E.J., Naidoo, J., et al. (2019) Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists after Immunotherapy Cessation. Annals of the Rheumatic Diseases, 79, 332-338. [Google Scholar] [CrossRef] [PubMed]
[42] Hoa, S., Laaouad, L., Roberts, J., Ennis, D., Ye, C., Al Jumaily, K., et al. (2021) Preexisting Autoimmune Disease and Immune-Related Adverse Events Associated with Anti-Pd-1 Cancer Immunotherapy: A National Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology. Cancer Immunology, Immunotherapy, 70, 2197-2207. [Google Scholar] [CrossRef] [PubMed]
[43] Dolladille, C., Ederhy, S., Sassier, M., Cautela, J., Thuny, F., Cohen, A.A., et al. (2020) Immune Checkpoint Inhibitor Rechallenge after Immune-Related Adverse Events in Patients with Cancer. JAMA Oncology, 6, 865-871. [Google Scholar] [CrossRef] [PubMed]
[44] Kim, S.T., Chu, Y., Misoi, M., Suarez-Almazor, M.E., Tayar, J.H., Lu, H., et al. (2022) Distinct Molecular and Immune Hallmarks of Inflammatory Arthritis Induced by Immune Checkpoint Inhibitors for Cancer Therapy. Nature Communications, 13, Article No. 1970. [Google Scholar] [CrossRef] [PubMed]
[45] Nuñez, N.G., Berner, F., Friebel, E., Unger, S., Wyss, N., Gomez, J.M., et al. (2023) Immune Signatures Predict Development of Autoimmune Toxicity in Patients with Cancer Treated with Immune Checkpoint Inhibitors. Med, 4, 113-129.E7. [Google Scholar] [CrossRef] [PubMed]
[46] Berner, F. and Flatz, L. (2023) Autoimmunity in Immune Checkpoint Inhibitor‐Induced Immune‐Related Adverse Events: A Focus on Autoimmune Skin Toxicity and Pneumonitis. Immunological Reviews, 318, 37-50. [Google Scholar] [CrossRef] [PubMed]

为你推荐